ResearchMoz

Espicom Market Research Reports

With over 30 years of continuous research and editorial experience in the global health industry, Espicom is one of the longest established independent business intelligence providers operating today. 
Espicom produces original analysis, news and forecasts using its skilled and experienced team of more than 30 full-time in-house analysts, researchers and editorial experts. With a combined experience of over 200 years they cover key disciplines including pharmacology, biosciences, economics statistics and languages. In addition, a select group of experts are on hand in respect of specialist scientific/technology areas. We do not use freelancers or subcontractors to produce our class leading subscription and intelligence services. This gives us control and you confidence. 

List of reports from Espicom

Displaying 1 to 30 (of 211 records)
The Pharmaceutical Market: Namibia
Jan 2015  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN NAMIBIA Namibia has many of the qualities exhibited by frontier pharmaceutical markets: very low percapita spending on medicines, limited access to healthcare facilities, a high prevalence of communicable diseases and constrained ability to pay for advanced therapeutics. Nevertheless, due to low growth rates in developed states,...
$1295
The Pharmaceutical Market: Puerto Rico
Dec 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN PUERTO RICO The outcome of the upcoming elections is expected to assist in shaping the development of Puerto Rico's healthcare and pharmaceutical markets, depending on the direction of the new governor's economic policies. Nevertheless, we do not expect a return to the historically-high annual rates of pharmaceutical spending,...
$1295
The Pharmaceutical Market: Oman
Dec 2014  
Oman Pharmaceuticals & Healthcare Report Oman's commendable public healthcare system and high-class tertiary and quaternary care hospitals will increase the uptake of medical tourism by GCC citizens. The Omani pharmaceutical market will continue to remain heavily reliant on imports due to the costly need to source raw ingredients for local manufacturing and lack of R&D...
$1295
The Pharmaceutical Market: Colombia
Dec 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN COLOMBIA Improvements in Colombia's pharmaceutical re gulation system will expand local patients' access to medicines. However, it will also p ut pricing pressure s on drugmakers, and promote the use of generic versions, which will undermine the growth of patented drug market. Nevertheless, BMI expects more foreign pharmaceutical co...
$1295
The Pharmaceutical Market: Bangladesh
Dec 2014  
THE PHARMACEUTICAL MARKET: BANGLADESH - REVIEW While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies, such as Bangladesh, may be a favourable strategy for any multinational pharmaceutical company - it is vital that a company recognises both the rewards and the risks present in a market. With regards to assessing...
$1295
The Pharmaceutical Market: Kazakhstan
Dec 2014  
Kazakhstan Pharmaceuticals & Healthcare Report Kazakhstan ' s pharmaceutical market remains the most accessible, transparent and, from a legislative point of view, progressive in Central Asia. In terms of market size, its potential is limited by its relatively small population (15mn) and logistical challenges. In the short term, Kazakhstan ' s market development is driven...
$1295
The Pharmaceutical Market: Sudan & South Sudan
Dec 2014  
Sudan & South Sudan Pharmaceuticals & Healthcare Report Sudan and South Sudan's will continue to be of least interest to foreign pharmaceutical firms in the Middle East and North Africa region as the countries are plagued by high inflation, fiscal constraints and underdeveloped non-oil economies. Political risk remains elevated as many disputes between them are still...
$1295
The Pharmaceutical Market: Taiwan
Dec 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN TAIWAN We continue to view Taiwan as a challenging market for multinationals, mostly on account of the difficult pricing and reimbursement environment, which is due to undergo further changes. Specifically, as part of the Second Generation National Health Insurance (NHI) programme, which becomes effective in 2013, a new reimbursement...
$1295
The Pharmaceutical Market: Myanmar
Dec 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN MYANMAR Despite its small size, Myanmar's pharmaceutical market offers drugmakers strong revenue-earning opportunities. Generic and over-the-counter drug companies in particular stand to benefit, as the population's per capita expenditure on pharmaceuticals and healthcare remains low but set to rise. However we believe that the country...
$1295
The Pharmaceutical Market: Lebanon
Dec 2014  
Lebanon Pharmaceuticals & Healthcare Report Although this quarter has seen a number of regulatory initiatives taken by the Lebanese Minister of Health, Ali Hassan Khalil , to improve the state of the pharmaceutical industry, we maintain that a multilateral approach is required to improve foreign direct investment (FDI) in to the country and that , in the short to medium...
$1295
The Pharmaceutical Market: Turkey
Nov 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN TURKEY The cooling economic environment and the weakening lira has moderated optimistic forecasts on the Turkish pharmaceutical market, especially as the government is the single largest reimburser of pharmaceuticals, covering 80-85% of total drug expenditure through various insurance and immunisation schemes. Price cutting and public...
$1295
The Pharmaceutical Market: Zambia
Nov 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN ZAMBIA The majority of investment in Zambia's healthcare market stems from international aid agencies - so the news that the government has increased its allocation for healthcare spending in the 2013 budget will be well received by both NGOs and international investors as a sign that Zambia is taking its commitment to healthcare...
$1295
The Pharmaceutical Market: The Netherlands
Nov 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN THE NETHERLANDS While the Netherlands is a low-risk market from the point of view of multinational drugmakers, the country's modest per capita expenditure on pharmaceuticals relative to other Western European countries is an issue. Another challenge facing drugmakers is cost-containment, which will only intensify as the Netherlands...
$1295
The Pharmaceutical Market: Germany
Nov 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN GERMANY While the Arzneimittelmarkt-Neuordnungsgesetz ( AMNOG ) legislation will compress drug companies' revenue-earning opportunities in Germany, we believe the government's decision to make the final reimbursement prices of medicines sold in the country publicly available, and the use of reference pricing across the region, will also...
$1295
The Pharmaceutical Market: Austria
Nov 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN AUSTRIA The macroenvironment for the Austrian pharmaceutical industry is positive. Economic recovery is strengthening, with modest GDP real growth projected in 2012 and 2013. However, the EIU projects that Austria will be affected by the expected euro zone recession. Legally, laws on intellectual property and patent provision are in...
$1295
The Pharmaceutical Market: South Africa
Jul 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SOUTH AFRICA The government drive to support local production and reduce the country's reliance on imports, in addition to global epidemiological and demographic trends, are all positive factors contributing to long-term growth in the pharmaceutical market. However, deep segregation between private and public healthcare facilities...
$1295
The Pharmaceutical Market: United Arab Emirates
Jul 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN UNITED ARAB EMIRATES The United Arab Emirates'healthcare and pharmaceutical markets continue to be thestrongest in the region.Its growth prospects arestrong -we forecast high single-digit CAGRsover the course of our 10-year forecast period. Several factors are driving growth: incomes are high, as isthe UAE's expatriate population.These...
$1295
The Pharmaceutical Market: Qatar
Jul 2014  
Qatar Pharmaceuticals & Healthcare Report According to recent reports in The Gulf Times, Qatar will have four new drug manufacturers by the end of Q113. The drugmakers will reportedly import their raw materials and produce tablets, syrups and injectables. It is anticipated the drug manufacturers will (in our view eventually) help curb reliance on imports and lower prices...
$1295
The Medical Device Market: USA
Jul 2014  
OVERVIEW OF THE MEDICAL MARKET IN THE USA At an estimated US$127.1bn in 2013, the US medical device market is the world's largest. Per capita expenditure, at US$399, is the highest in the world. Much of the market is in private hands; there is no single health system. Public healthcare systems, known as Medicaid, for those on low incomes, are operated by each State....
$1295
The Pharmaceutical Market: Slovakia
Jul 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SLOVAKIA Slovak Prime Minister Robert Fico plans to unify the country'sprivate and public health insurance funds into a single state-owned insurer, but there is likely to be a lengthy negotiation and a legal battle before this is realised. We do not expect either of the two private insurers - Dôvera or Dutch-owned Union - will...
$1295
The Medical Device Market: Bangladesh
Jul 2014  
OVERVIEW OF THE MEDICAL MARKET IN BANGLADESH Bangladesh remains one of the poorest countries in the world. Poverty is widespread throughout and GDP is extremely low, despite it being the eighth most populous country on earth. Frequent large scale flooding also remains a constant threat. Government funding is low and the country continues to rely on international aid. An...
$1295
The Pharmaceutical Market: Ghana
Jul 2014  
Ghana Pharmaceuticals & Healthcare Report We remain of the view that Ghana will be a regional outperformer in terms of the development of its pharmaceutical and healthcare markets over the medium to longer term . On the other hand, reliance on donations and foreign aid to provide some of the medical services and treatments will continue to negatively impact the development...
$1295
The Medical Device Market: Germany
Jul 2014  
OVERVIEW OF THE MEDICAL MARKET IN GERMANY Germany has one of the most advanced economies in the world. GDP is estimated at US$3.6trn in 2013, equal to around US$44,000 per capita, making the German economy the fourth largest, behind the USA, China and Japan. As one of the world's largest exporters, the German economy has been hard hit by the poor global economic climate...
$1295
The Medical Device Market: Romania
Jul 2014  
OVERVIEW OF THE MEDICAL MARKET IN ROMANIA Romania spends around 5.8% of GDP on healthcare. Government health expenditure is very low, even by Eastern European standards. However, improvements to the health system continue to be supported by World Bank-sponsored projects. The 'Health Sector Reform Project APL II', was approved in December 2004 and will run until December 2013....
$1295
The Pharmaceutical Market: Indonesia
Jul 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN INDONESIA Indonesia's new goal to establish universal healthcare coverage by 2019 rather than 2014 is more feasible given that the programme will be rolled out in phases. We continue to see universal healthcare coverage as a key theme in Asia, although poor governance in several countries across the region will delayitsimplementation....
$1295
The Pharmaceutical Market: Norway
Jul 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN NORWAY The macroenvironment for the Norwegian pharmaceutical industry is improving. Politically, the centre-left coalition is expected to hold together at least until the general election in September 2013, but the risk of the coalition breaking up has grown. Economically, the recession was far less pronounced in Norway than in most...
$1295
The Pharmaceutical Market: Vietnam
Jul 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN VIETNAM Corruption will continue to affect Vietnam's pharmaceutical and healthcare business environment and potentially delay the introduction of universal healthcare coverage for its people. While corruption is a clear downside risk, we maintain that the sector still offers strong growth opportunities for foreign investors....
$1295
The Medical Device Market: Austria
Jul 2014  
OVERVIEW OF THE MEDICAL MARKET IN AUSTRIA Although a relatively small market, Austria has a high level of per capita spending on medical devices. The market for medical equipment and supplies is valued at US$2,527mn in 2013, equal to US$299 per capita. Austria is a federal republic, comprising nine constituent federal states: Burgenland, Carinthia, Lower Austria, Salzburg,...
$1295
The Medical Device Market: Colombia
Jul 2014  
OVERVIEW OF THE MEDICAL MARKET IN COLOMBIA Colombia is the third most populous country in Latin America, behind Brazil and Mexico, with a population of 48mn. The capital, Santa Fe de Bogotá, has a population of around 7mn. The population is relatively young and growing rapidly thanks to a high birth rate and a low mortality rate. Colombia is the fourth largest...
$1295
The Medical Device Market: Poland
Jun 2014  
OVERVIEW OF THE MEDICAL MARKET IN POLAND Poland has the second largest economy in Central & Eastern Europe, although in per capita terms it is around average. According to BMI, GDP is estimated at US$529.0bn in 2013 and is expected to increase by an average 3.5% per annum between 2014 and 2018, reaching US$733.7bn. GDP per capita will rise from US$13,800 in 2013...
$1295
 
Displaying 1 to 30 (of 211 records)

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us

Popular Publishers

Transparency Market Research
ICD Research
Technavio
 
GBI Research
Winter Green Research
GlobalData